DK1492539T3 - Statin-terapi til forögelse af kognitiv funktion - Google Patents
Statin-terapi til forögelse af kognitiv funktionInfo
- Publication number
- DK1492539T3 DK1492539T3 DK03745196T DK03745196T DK1492539T3 DK 1492539 T3 DK1492539 T3 DK 1492539T3 DK 03745196 T DK03745196 T DK 03745196T DK 03745196 T DK03745196 T DK 03745196T DK 1492539 T3 DK1492539 T3 DK 1492539T3
- Authority
- DK
- Denmark
- Prior art keywords
- cognitive function
- statin
- statin therapy
- enhance cognitive
- galantamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1492539T3 true DK1492539T3 (da) | 2006-10-30 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03745196T DK1492539T3 (da) | 2002-04-02 | 2003-03-28 | Statin-terapi til forögelse af kognitiv funktion |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (da) |
| JP (1) | JP2005525391A (da) |
| KR (1) | KR100986194B1 (da) |
| CN (1) | CN100528164C (da) |
| AT (1) | ATE331523T1 (da) |
| AU (1) | AU2003226753B2 (da) |
| BR (1) | BR0308293A (da) |
| CA (1) | CA2480275C (da) |
| CY (1) | CY1105545T1 (da) |
| DE (1) | DE60306503T2 (da) |
| DK (1) | DK1492539T3 (da) |
| EA (1) | EA013069B1 (da) |
| ES (1) | ES2268393T3 (da) |
| HK (1) | HK1079688A1 (da) |
| IL (2) | IL164317A0 (da) |
| MX (1) | MXPA04009535A (da) |
| NO (1) | NO20044698L (da) |
| NZ (1) | NZ536111A (da) |
| PL (1) | PL211160B1 (da) |
| PT (1) | PT1492539E (da) |
| UA (1) | UA79605C2 (da) |
| WO (1) | WO2003082298A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| CA2562069A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of alzheimers disease |
| US20050272804A1 (en) * | 2004-06-08 | 2005-12-08 | Axonyx, Inc | Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| US20080103105A1 (en) * | 2006-09-22 | 2008-05-01 | Braincells, Inc. | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| WO2015089349A1 (en) * | 2013-12-13 | 2015-06-18 | Tabaczynski David A | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
-
2003
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en active IP Right Grant
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko active IP Right Grant
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2005
- 2005-12-21 HK HK05111808.4A patent/HK1079688A1/xx not_active IP Right Cessation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60306503T2 (de) | 2007-06-21 |
| NZ536111A (en) | 2006-03-31 |
| ES2268393T3 (es) | 2007-03-16 |
| KR100986194B1 (ko) | 2010-10-07 |
| WO2003082298A1 (en) | 2003-10-09 |
| MXPA04009535A (es) | 2005-01-25 |
| AU2003226753B2 (en) | 2007-06-28 |
| PL211160B1 (pl) | 2012-04-30 |
| EA200401295A1 (ru) | 2005-02-24 |
| JP2005525391A (ja) | 2005-08-25 |
| KR20040096608A (ko) | 2004-11-16 |
| AU2003226753A1 (en) | 2003-10-13 |
| CY1105545T1 (el) | 2010-07-28 |
| BR0308293A (pt) | 2004-12-28 |
| CN1642555A (zh) | 2005-07-20 |
| EA013069B1 (ru) | 2010-02-26 |
| ATE331523T1 (de) | 2006-07-15 |
| UA79605C2 (en) | 2007-07-10 |
| CA2480275C (en) | 2011-08-16 |
| PL371551A1 (en) | 2005-06-27 |
| EP1492539B1 (en) | 2006-06-28 |
| HK1079688A1 (en) | 2006-04-13 |
| DE60306503D1 (de) | 2006-08-10 |
| CA2480275A1 (en) | 2003-10-09 |
| IL164317A0 (en) | 2005-12-18 |
| IL164317A (en) | 2010-04-29 |
| PT1492539E (pt) | 2006-11-30 |
| EP1492539A1 (en) | 2005-01-05 |
| NO20044698L (no) | 2004-10-29 |
| CN100528164C (zh) | 2009-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| BRPI0415858A (pt) | compostos de medicamentos terapêuticos modificados por tocoferol | |
| ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| DE602004031631D1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| BG105342A (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
| DE602004029993D1 (de) | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
| HUP0300043A2 (en) | Method and composition for the treatment of pain | |
| DE60122764D1 (de) | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen | |
| WO2003066806A3 (en) | Therapeutic use of aziridino compounds | |
| ATE334675T1 (de) | Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole | |
| ATE353221T1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa |